U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309289) titled 'NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer' on Dec. 15.
Brief Summary: To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer (CRC)
Intervention:
DRUG: NALIRIFOX plus targeted therapy
Drug: Irinotecan Liposome Irinotecan liposome injection will be administered by an intravenous infusion at the dose of 50 mg/m^2, d1, 14 days per cycle.
Drug: Oxali...